PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 27, 2024Science Advances70 citationsOpen Access

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

View Full Paper
RPRay PillaiSLSarah E. LeBoeufYHYuan Hao

Key Points

Key points are not available for this paper at this time.

Abstract

Loss-of-function mutations in

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pillai et al. (2024) studied this question.

synapsesocial.com/papers/68e720ddb6db64358769aed9https://doi.org/10.1126/sciadv.adm9859
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SLC38A6 expression in macrophages exacerbates pulmonary inflammation2023 · 8 citations
  2. 2Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR2010 · 5,602 citations
  3. 3STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort2020 · 246 citations
  4. 4Hallmarks of Cancer: The Next Generation2011 · 67,359 citations
  5. 5Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer2022 · 180 citations